✦ LIBER ✦

OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial

✍ Scribed by D Salmon-Céron, C Durier, C Desaint, Cuzin, M Surenaud, Y Hénin…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of a novel hum

✍ Yan-Ping Li; Zheng-Lun Liang; Qiang Gao; Li-Rong Huang; Qun-Ying Mao; Shu-Qun We 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 542 KB

Safety and immunogenicity of SC599, an o

✍ Odile Launay; Christine Sadorge; Nathalie Jolly; Béatrice Poirier; Stéphane Béch 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 795 KB

Safety and efficacy of the peptide-based

✍ Pollard, Richard B; Rockstroh, Jürgen K; Pantaleo, Giuseppe; Asmuth, David M; Pe 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 458 KB

Immunogenicity and safety of an enterovi

✍ Zhu, Feng-Cai; Liang, Zheng-Lun; Li, Xiu-Ling; Ge, Heng-Ming; Meng, Fan-Yue; Mao 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 166 KB

A randomized, double-blind, placebo-cont

✍ David I. Bernstein; Judith Falloon; Tingting Yi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 596 KB

Immunogenicity and safety of a new menin

✍ Siddhivinayak Hirve; Ashish Bavdekar; Anand Pandit; Sanjay Juvekar; Malini Patil 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 311 KB